News and Media
CANTON, Mich. (July 20, 2020) – MMS Holdings Inc. (MMS) – an award-winning, data-focused CRO – announced that it has been recognized by Corporate LiveWire as the Most Innovative Clinical Research Organization (CRO) in the United States.
By Rob DiCicco, June 11, 2020
The novel coronavirus (COVID-19) pandemic is an unprecedented crisis that has galvanized the global scientific community around the search for a viable vaccine and effective therapies. This incredible commitment to science may ultimately pay dividends, but each passing day is critical as we seek to stem the tide of this deadly pandemic. There is a collective sense of urgency to consider incremental ways to expediate the process to get treatments to patients and our IBM® Clinical Development (ICD) solution is designed to help address a challenge such as this.
THUNDER BAY, ONTARIO (June 08, 2020) – IGY Life Sciences today announced it will be collaborating with clinical data and regulatory experts, MMS Holdings (MMS), to further the development of IgY-110, an anti-CoV2 therapeutic antibody with a focus on a nasal spray application. This novel approach of an IgY antibody in a nasal spray will be complementary to any vaccine developed.
University of Michigan School of Information Invites MMS Holdings Executive Kelly J. Hill to Join External Advisory Board
CANTON, Mich. (May 19, 2020) – MMS Holdings Inc. (MMS) – an award-winning, data-focused CRO – announced today that its Executive Director of Global Business Operations and Strategy Kelly J. Hill has accepted an invitation to join the University of Michigan School of Information (UMSI) External Advisory Board (EAB).
GREEN VALLEY PHARMACEUTICAL AND MMS HOLDINGS COLLABORATE TO GAIN FDA APPROVAL TO BEGIN CLINICAL TRIALS FOR THE FIRST ALZHEIMER’S DRUG IN 17 YEARS
CANTON, Mich. and SHANGHAI (May 5, 2020) – MMS announced that a successful collaboration with Shanghai-based Green Valley Pharmaceutical Co. (Green Valley) resulted in gaining U.S. Food & Drug Administration (FDA) approval of an Investigational New Drug (IND) application for the GV-971 international multi-center Phase III clinical study in the treatment of patients with Alzheimer’s disease.
FORMER GILEAD SCIENCES HEAD OF CLINICAL TRIAL DISCLOSURE AND DATA TRANSPARENCY JOINS MMS AND TRIALASSURE AS DIRECTOR OF GLOBAL TRANSPARENCY STRATEGY AND COMPLIANCE
CANTON, Mich. (April 16, 2020) – MMS announced today the addition of Kelly Vaillant as Director, Global Transparency Strategy and Compliance. Vaillant will lead the transparency and compliance efforts across MMS and TrialAssure global operations. TrialAssure is the technology arm of MMS and a leading, global software company focused on advancing clinical trial transparency.
MMS ANNOUNCES ONE MILLION DOLLAR AWARD FOR PHARMACEUTICAL COMPANIES DEVELOPING A VACCINE FOR COVID-19
Canton, Mich. (March 20, 2020) — MMS Holdings announced today that it is offering a USD1M award toward the development of a vaccine for COVID-19, also known as the coronavirus. The award is being offered in the form of data and related services to qualified pharmaceutical and clinical research companies supporting the commercial development of a vaccine for approval in the United States and/or other global health authorities.
by Prasad M. Koppolu, March 12, 2020
I would like to take a moment and share our commitment to the highest levels of health and improving lives worldwide, amidst the outbreak of COVID-19.
MMS HOLDINGS TO DEBUT DATACISE INTEGRATED SAFETY EXPLORER TO DETECT SAFETY SIGNALS USING REAL-WORLD EVIDENCE DURING PHUSE/FDA DATA SCIENCE INNOVATION CHALLENGE
CANTON, Mich. (March 4, 2020) – MMS Holdings (MMS) – an award-winning, data-focused CRO – announced today that the Datacise Integrated Safety Explorer will make its debut at the 2020 PHUSE U.S. Connect conference in Orlando, Florida as part of the PHUSE/FDA Data Science Innovation Challenge, where, according to PHUSE, the “greatest minds in the data sciences arena come together and collaborate.”
BLOEMFONTEIN, South Africa (November 20, 2019) – MMS Holdings (MMS) – an award-winning, data-focused CRO – announced today that its regional operations in South Africa has more than doubled in the past fiscal year, through the addition of new colleagues in Bloemfontein and the successful procurement of key contracts with clinical trial sponsors and research groups.